Literature DB >> 8649548

Neurologic consequences of HTLV-II infection in injection-drug users.

G Dooneief1, R Marlink, K Bell, K Marder, B Renjifo, Y Stern, R Mayeux.   

Abstract

Several case reports have suggested an association between human T-cell lymphotropic virus type II (HTLV-II) infection and chronic neurologic disease. We performed serial neurologic examinations in injection-drug users (IDU), a group known to be at increased risk for HTLV-II infection. At baseline, those infected with HTLV-II alone, human immunodeficiency virus (HIV) alone, or both were significantly more likely to have neurologic disability than uninfected subjects. Longitudinally, HTLV-II infection was independently associated with the development of global neurologic disability and neuropathy, suggesting that HTLV-II causes neurologic disease.

Entities:  

Mesh:

Year:  1996        PMID: 8649548     DOI: 10.1212/wnl.46.6.1556

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  6 in total

Review 1.  Comparative biology of human T-cell lymphotropic virus type 1 (HTLV-1) and HTLV-2.

Authors:  Gerold Feuer; Patrick L Green
Journal:  Oncogene       Date:  2005-09-05       Impact factor: 9.867

2.  The receptor complex associated with human T-cell lymphotropic virus type 3 (HTLV-3) Env-mediated binding and entry is distinct from, but overlaps with, the receptor complexes of HTLV-1 and HTLV-2.

Authors:  Kathryn S Jones; Ying K Huang; Sébastien A Chevalier; Philippe V Afonso; Cari Petrow-Sadowski; Daniel C Bertolette; Antoine Gessain; Francis W Ruscetti; Renaud Mahieux
Journal:  J Virol       Date:  2009-03-11       Impact factor: 5.103

3.  Human T-lymphotropic virus type 2 (HTLV-2) provirus in circulating cells of the monocyte/macrophage lineage in patients dually infected with human immunodeficiency virus type 1 and HTLV-2 and having predominantly sensory polyneuropathy.

Authors:  G Zehender; L Meroni; S Varchetta; C De Maddalena; B Cavalli; M Gianotto; A B Bosisio; C Colasante; G Rizzardini; M Moroni; M Galli
Journal:  J Virol       Date:  1998-09       Impact factor: 5.103

4.  Neurologic abnormalities in HTLV-I- and HTLV-II-infected individuals without overt myelopathy.

Authors:  H H Biswas; J W Engstrom; Z Kaidarova; G Garratty; J W Gibble; B H Newman; J W Smith; A Ziman; J L Fridey; R A Sacher; E L Murphy
Journal:  Neurology       Date:  2009-09-08       Impact factor: 9.910

5.  Pathways of cell-cell transmission of HTLV-1.

Authors:  Claudine Pique; Kathryn S Jones
Journal:  Front Microbiol       Date:  2012-10-24       Impact factor: 5.640

6.  Characterizing the Interaction between the HTLV-1 Transactivator Tax-1 with Transcription Elongation Factor ELL2 and Its Impact on Viral Transactivation.

Authors:  Stephan Kohrt; Sarah Strobel; Melanie C Mann; Heinrich Sticht; Bernhard Fleckenstein; Andrea K Thoma-Kress
Journal:  Int J Mol Sci       Date:  2021-12-18       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.